欢迎您访问《中华养生保健》官方网站!

中华养生保健 ›› 2024, Vol. 42 ›› Issue (7): 13-15.

• 论著 • 上一篇    下一篇

普拉克索联合左旋多巴对帕金森病患者血清Hcy表达与肌张力的影响

胡蓉蓉   

  1. 渭南市第二医院神经内科,陕西 渭南,714000
  • 出版日期:2024-04-01 发布日期:2024-03-20

The Effect of Pramipexole Combined with Levodopa on Serum Hcy Expression and Muscle Tone in Patients with Parkinson's Disease

HU Rong-rong   

  1. Department of Neurology, Weinan Second Hospital, Weinan Shaanxi 714000, China
  • Online:2024-04-01 Published:2024-03-20

摘要: 目的 探讨普拉克索联合左旋多巴对帕金森病患者血清同型半胱氨酸(Homocysteine,HCY)表达水平与肌张力的影响。方法 选取2019年9月—2023年1月渭南市第二医院收治的86例帕金森病患者作为研究对象,根据1:1随机信封抽签原则分为联合组、传统组,各43例。传统组给予左旋多巴治疗,联合组给予左旋多巴联合普拉克索治疗,两组都治疗3个月,观察与记录两组患者血清同型半胱氨酸表达水平与肌张力变化情况、总有效率、不良反应发生情况及痫样放电、累及导联数。结果 治疗3个月后,联合组的总有效率显著高于传统组,差异有统计学意义(P<0.05)。治疗期间两组患者体位性低血压、嗜睡、头晕恶心、心悸等不良反应发生率比较,差异无统计学意义(P>0.05)。两组治疗3个月后的肌张力评分明显低于治疗前,联合组治疗3个月后的肌张力评分显著低于传统组,差异有统计学意义(P<0.05)。治疗3个月后,两组的血清同型半胱氨酸水平高于治疗前,但联合组治疗3个月后的血清同型半胱氨酸水平低于传统组,差异有统计学意义(P<0.05)。两组治疗3个月后的痫样放电、累及导联数低于治疗前,联合组治疗3个月后的痫样放电、累及导联数低于传统组,差异有统计学意义(P<0.05)。结论 普拉克索联合左旋多巴在帕金森病患者中的应用能提高总体治疗效果,减少不良反应的发生,抑制患者血清同型半胱氨酸的释放,改善患者肌张力,还可改善患者的脑电图状况。

关键词: 普拉克索, 左旋多巴, 帕金森病, 同型半胱氨酸, 肌张力, 脑电图

Abstract: Objective To investigate the effect of pramipexole combined with levodopa on serum homocysteine (HCY) expression and muscle tone in patients with Parkinson's disease. Methods From September 2019 to January 2023, 86 cases of patients with Parkinson's disease who were diagnosed and treated at the Second Hospital of Weinan City were selected as the research subjects and grouped according to the principle of 1:1 randomized envelope draw, i.e., the combination group and the traditional group, each with 43 cases. The traditional group was given levodopa treatment, while the conjoined group was treated with the addition of pramipexole, Both groups were treated and observed for 3 months, and overall effective rate of treatment,incidence of adverse effects, the expression of serum homocysteine, the change of muscle tension, epileptiform discharges, changes in number of involved leads were observed and recorded. Results After 3 months of treatment, the total effective rate of the combination group were 97.67%, while the traditional group were 86.05%. The combination group were significantly higher than the traditional group (P<0.05). The incidence of postural Hypotension, somnolence, dizziness, nausea, palpitation and other adverse reactions in the combination group were 2.33%, 4.65%, 4.65% and 2.33% respectively during the three months of treatment, while those in the traditional group were 4.65%, 2.33%, 4.65% and 4.65%, respectively. There were no significant difference between the two groups (P>0.05). The muscle tone scores of the two groups after 3 months of treatment were significantly lower than before treatment (P<0.05), and the muscle tone scores of the combination group after 3 months of treatment were also significantly lower compared to the traditional group (P<0.05). Serum homocysteine levels were higher in both groups after 3 months of treatment than before treatment (P<0.05), but serum homocysteine levels were lower in the combined group than in the conventional group after 3 months of treatment (P<0.05). After 3 months of treatment, the epileptiform discharge and number of involved leads in both groups were lower than before treatment (P<0.05), while the combination group had lower epileptiform discharge and number of involved leads after 3 months of treatment than the traditional group (P<0.05). Conclusion Pramipexole combined with levodopa in patients with Parkinson's disease can improve the overall therapeutic effect, reduce the occurrence of adverse reactions, inhibit the release of serum homocysteine, improve the patient's muscle tone, and improve the patient's Electroencephalography status.

Key words: pramipexole, levodopa, parkinson's disease, homocysteine, muscle tension, electroencephalography

中图分类号: